Pancreas Volume in Preclinical Type 1 Diabetes

临床前 1 型糖尿病的胰腺体积

基本信息

  • 批准号:
    8644494
  • 负责人:
  • 金额:
    $ 139.85万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-09-20 至 2017-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): For decades, type 1 diabetes (T1D) has been considered a disorder resulting from the autoimmune destruction of insulin producing pancreatic beta cells. What is often less appreciated, but is in fact equally well established, is the generalized atrophy of the pancreas in new onset T1D as well as in those with established disease. Recent studies by the applicants demonstrated that pancreas weight from organ donors with T1D was significantly reduced. However, and more profound, reductions in pancreas weight were also observed in organ donors with only single diabetes-related autoantibodies. These findings underscore that changes in pancreas weight may represent an early event in the pathogenesis of T1D and raise the intriguing idea that pancreatic volume may serve as a long desired "biomarker" for understanding both disease prediction as well as progression. This application seeks funding for a pilot study to determine whether noninvasive estimations of pancreas volume can be used as a prognostic tool in monitoring autoantibody positive, first-degree relatives of patients with T1D. We hypothesize that T1D is associated with progressive pancreatic atrophy that correlates with functional beta cell mass. We propose to examine pancreas volume in four study groups: controls (age and gender matched to autoantibody positive participants), single autoantibody positive participants, multiple autoantibody positive participants, and recent onset T1D patients. Subjects will be recruited through the NIH TrialNet "Pathway to Prevention" studies and the Pediatric and Adult Endocrinology units at the University of Florida Diabetes Center. Specific aims include: 1) Utilize noninvasive radiological imaging to determine pancreas volume in control subjects, subjects at increased risk for T1D (single and multiple autoantibody positive groups), and subjects with new onset T1D. Pancreas volume will be assessed by two noninvasive radiological methods, ultrasound (US) and magnetic resonance imaging (MRI). 2) Correlate pancreas volume with beta cell function and autoimmunity. This aim seeks to determine if biomarkers of beta cell function (fasting glucose, C-peptide and HbA1c) and T1D risk (autoantibodies) correlate with pancreas volume. 3) Correlate pancreas volume with T cell function subsets and HLA. This final aim seeks to determine whether T cell subset functional studies and HLA types can be utilized to explain variance in pancreatic volume amongst controls, at risk subjects, and subjects with new onset T1D. Innovative aspects of this proposal include application of a highly accessible, noninvasive, and relatively low cost imaging method to assess T1D pathogenesis and the combination of faculty in immunology, pathology, clinical endocrinology (pediatric and adult endocrinology), biostatistics, and radiology to form a highly interactive and complementary research team. If pancreatic volume could be monitored over time and one is able to identify a specific loss of functional beta cell mass which coincides with a certain threshold of pancreas volume, pancreas volume could represent a major complement to other biomarkers used for clinical prevention and intervention trials for patients at risk for T1D. As well, monitoring pancreatic volume over time could function as an accurate, noninvasive, and simple surrogate marker for disease progression, allowing timely and guided clinical care.
描述(申请人提供):几十年来,1型糖尿病(T1D)一直被认为是一种由于产生胰岛素的胰岛β细胞的自身免疫破坏而引起的疾病。新发的T1D患者和既往疾病患者的胰腺普遍萎缩,这一点通常不太被认识到,但实际上同样得到了很好的证实。申请者最近的研究表明,患有T1D的器官捐赠者的胰腺重量显著减轻。然而,更深刻的是,只有一种糖尿病相关自身抗体的器官捐赠者也观察到胰腺重量的减轻。这些发现强调,胰腺重量的变化可能代表了T1D发病机制中的早期事件,并提出了一个有趣的想法,即胰腺体积可能是理解疾病预测和进展的长期理想的“生物标志物”。这项申请寻求资金用于一项先导性研究,以确定对胰腺体积的非侵入性估计是否可以用作监测自身抗体阳性的T1D患者的一级亲属的预后工具。我们假设T1D与进行性胰腺萎缩有关,而进行性胰腺萎缩与功能性β细胞团相关。我们建议在四个研究组中检测胰腺体积:对照组(年龄和性别与自身抗体阳性的参与者匹配)、单一自身抗体阳性的参与者、多个自身抗体阳性的参与者以及新近发病的T1D患者。受试者将通过NIH TrialNet“预防之路”研究以及佛罗里达大学糖尿病中心的儿科和成人内分泌科招募。具体目标包括:1)利用 非侵入性放射成像以确定对照受试者、T1D高危受试者(单一和多个自身抗体阳性组)和新发T1D受试者的胰腺体积。胰腺体积将通过两种非侵入性放射学方法进行评估,即超声(US)和磁共振成像(MRI)。2)胰腺体积与胰岛β细胞功能和自身免疫相关。这一目标旨在确定β细胞功能的生物标记物(空腹血糖、C肽和HbA1c)和T1D风险(自身抗体)是否与胰腺体积相关。3)胰腺体积与T细胞功能亚群及人类白细胞抗原相关。最终目的是确定T细胞亚群功能研究和人类白细胞抗原分型是否可以用来解释对照组、高危受试者和新发T1D受试者之间胰腺体积的差异。这项建议的创新方面包括应用一种高度可访问、非侵入性和相对低成本的成像方法来评估T1D的发病机制,并将免疫学、病理学、临床内分泌学(儿童和成人内分泌学)、生物统计学和放射学的教职员工结合起来,组成一个高度互动和互补的研究团队。如果可以随着时间的推移监测胰腺体积,并且能够识别与某个胰腺体积阈值一致的特定的功能性β细胞质量损失,那么胰腺体积可能是对其他用于T1D风险患者临床预防和干预试验的生物标志物的主要补充。此外,随着时间的推移监测胰腺体积可以作为疾病进展的准确、非侵入性和简单的替代标记物,允许及时和指导临床护理。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
Pancreatic duct hyperplasia/dysplasia in type 1 diabetes and pancreatic weight in individuals with and without diabetes. Reply to Kobayashi T, Aida K, Fukui T et al [letter] and Saisho Y [letter].
1 型糖尿病中的胰管增生/发育不良以及患有和不患有糖尿病的个体的胰腺重量。
  • DOI:
    10.1007/s00125-016-3889-4
  • 发表时间:
    2016
  • 期刊:
  • 影响因子:
    8.2
  • 作者:
    Campbell-Thompson,MarthaL;Schatz,DesmondA;Kaddis,JohnS;Atkinson,MarkA
  • 通讯作者:
    Atkinson,MarkA
New insight on human type 1 diabetes biology: nPOD and nPOD-transplantation.
  • DOI:
    10.1007/s11892-014-0530-0
  • 发表时间:
    2014-10
  • 期刊:
  • 影响因子:
    4.2
  • 作者:
    Pugliese, Alberto;Vendrame, Francesco;Reijonen, Helena;Atkinson, Mark A.;Campbell-Thompson, Martha;Burke, George W.
  • 通讯作者:
    Burke, George W.
Abnormalities of the Exocrine Pancreas in Type 1 Diabetes.
  • DOI:
    10.1007/s11892-015-0653-y
  • 发表时间:
    2015-10
  • 期刊:
  • 影响因子:
    4.2
  • 作者:
    Campbell-Thompson, Martha;Rodriguez-Calvo, Teresa;Battaglia, Manuela
  • 通讯作者:
    Battaglia, Manuela
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARTHA CAMPBELL-THOMPSON其他文献

MARTHA CAMPBELL-THOMPSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARTHA CAMPBELL-THOMPSON', 18)}}的其他基金

Understanding pancreatic endocrine and exocrine loss in pre-type 1 diabetes
了解 1 型糖尿病前期的胰腺内分泌和外分泌丧失
  • 批准号:
    10461979
  • 财政年份:
    2020
  • 资助金额:
    $ 139.85万
  • 项目类别:
Multi-omic 3D tissue maps for a Human BioMolecular Atlas
人类生物分子图谱的多组学 3D 组织图谱
  • 批准号:
    10685583
  • 财政年份:
    2020
  • 资助金额:
    $ 139.85万
  • 项目类别:
Understanding pancreatic endocrine and exocrine loss in pre-type 1 diabetes
了解 1 型糖尿病前期的胰腺内分泌和外分泌丧失
  • 批准号:
    10226911
  • 财政年份:
    2020
  • 资助金额:
    $ 139.85万
  • 项目类别:
Pathways and critical regulators of early beta-cell dysfunction in type 1 diabetes
1 型糖尿病早期 β 细胞功能障碍的途径和关键调节因子
  • 批准号:
    10202585
  • 财政年份:
    2019
  • 资助金额:
    $ 139.85万
  • 项目类别:
Pathways and critical regulators of early beta-cell dysfunction in type 1 diabetes
1 型糖尿病早期 β 细胞功能障碍的途径和关键调节因子
  • 批准号:
    10441263
  • 财政年份:
    2019
  • 资助金额:
    $ 139.85万
  • 项目类别:
Pathways and critical regulators of early beta-cell dysfunction in type 1 diabetes
1 型糖尿病早期 β 细胞功能障碍的途径和关键调节因子
  • 批准号:
    9802936
  • 财政年份:
    2019
  • 资助金额:
    $ 139.85万
  • 项目类别:
Neuromodulation-based treatment of diabetes: identifying anatomical and physiological pancreatic innervation targets
基于神经调节的糖尿病治疗:确定解剖学和生理学胰腺神经支配目标
  • 批准号:
    9752693
  • 财政年份:
    2016
  • 资助金额:
    $ 139.85万
  • 项目类别:
Defining Islet Heterogeneity Using Single Islet Transcriptomics
使用单胰岛转录组学定义胰岛异质性
  • 批准号:
    8812982
  • 财政年份:
    2014
  • 资助金额:
    $ 139.85万
  • 项目类别:
Leica Laser Microdissection Microscope for a Shared Resource
共享资源的徕卡激光显微切割显微镜
  • 批准号:
    8448032
  • 财政年份:
    2013
  • 资助金额:
    $ 139.85万
  • 项目类别:
Pathology/Immunology Core
病理学/免疫学核心
  • 批准号:
    8319521
  • 财政年份:
    2011
  • 资助金额:
    $ 139.85万
  • 项目类别:

相似国自然基金

靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    0 万元
  • 项目类别:
    面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
  • 批准号:
    2023JJ50274
  • 批准年份:
    2023
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    33 万元
  • 项目类别:
    地区科学基金项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
  • 批准号:
    n/a
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
  • 批准号:
    81973577
  • 批准年份:
    2019
  • 资助金额:
    55.0 万元
  • 项目类别:
    面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
  • 批准号:
    81602908
  • 批准年份:
    2016
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
  • 批准号:
    81501928
  • 批准年份:
    2015
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
  • 批准号:
    2341426
  • 财政年份:
    2024
  • 资助金额:
    $ 139.85万
  • 项目类别:
    Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
  • 批准号:
    2341424
  • 财政年份:
    2024
  • 资助金额:
    $ 139.85万
  • 项目类别:
    Continuing Grant
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政​​策的情绪动态
  • 批准号:
    10108433
  • 财政年份:
    2024
  • 资助金额:
    $ 139.85万
  • 项目类别:
    EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
  • 批准号:
    MR/X032809/1
  • 财政年份:
    2024
  • 资助金额:
    $ 139.85万
  • 项目类别:
    Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
  • 批准号:
    MR/X034690/1
  • 财政年份:
    2024
  • 资助金额:
    $ 139.85万
  • 项目类别:
    Fellowship
Walkability and health-related quality of life in Age-Friendly Cities (AFCs) across Japan and the Asia-Pacific
日本和亚太地区老年友好城市 (AFC) 的步行适宜性和与健康相关的生活质量
  • 批准号:
    24K13490
  • 财政年份:
    2024
  • 资助金额:
    $ 139.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Discovering the (R)Evolution of EurAsian Steppe Metallurgy: Social and environmental impact of the Bronze Age steppes metal-driven economy
发现欧亚草原冶金的(R)演变:青铜时代草原金属驱动型经济的社会和环境影响
  • 批准号:
    EP/Z00022X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 139.85万
  • 项目类别:
    Research Grant
ICF: Neutrophils and cellular senescence: A vicious circle promoting age-related disease.
ICF:中性粒细胞和细胞衰老:促进与年龄相关疾病的恶性循环。
  • 批准号:
    MR/Y003365/1
  • 财政年份:
    2024
  • 资助金额:
    $ 139.85万
  • 项目类别:
    Research Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
  • 批准号:
    2335955
  • 财政年份:
    2024
  • 资助金额:
    $ 139.85万
  • 项目类别:
    Standard Grant
Shaping Competition in the Digital Age (SCiDA) - Principles, tools and institutions of digital regulation in the UK, Germany and the EU
塑造数字时代的竞争 (SCiDA) - 英国、德国和欧盟的数字监管原则、工具和机构
  • 批准号:
    AH/Y007549/1
  • 财政年份:
    2024
  • 资助金额:
    $ 139.85万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了